During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to research ...

Mitochondrial mutation MT haplogroup T strongly predicts poor response to immune checkpoint inhibitors in metastatic melanoma ...

Zeynep Eroglu, MD, discusses the use of a triplet regimen vs standard doublet therapy for the treatment of brain metastases in patients with melanoma.

Quiescence in melanoma is not a rare and static state but a dynamic and reversible condition accessible to most tumor cells, ...

Patients with metastatic melanoma in mitochondrial haplogroup T are significantly less likely to respond to immunotherapy.